RxDoctor Payments Data

Dustaff Persaud, PA

Physician Assistant · Muscatine, IANPI 1013097856

Payments from drug & device makers

$759in general payments, 2019–2025

Across 37 payments — averaging $20.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$150
  • Novo Nordisk$127
  • AbbVie$122
  • AstraZeneca$101
  • Pfizer$57
  • Exact Sciences$46
  • plus $156 from 6 others

What the payments were for

  • Food & beverage$759100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$759 in reported general payments places this provider in the 80th percentile of 1,140 physician assistant providers in Iowa.

See all physician assistant providers in Iowa

Medicare billing

Part B allowed, 2024
$59,015
Medicare patients
199
Services billed
943

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban56$48,388
OzempicSemaglutide41$48,239
FarxigaDapagliflozin Propanediol25$24,416
XareltoRivaroxaban22$20,637
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$18,468
JanuviaSitagliptin Phosphate15$12,016
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog35$8,737
Stiolto RespimatTiotropium Br/Olodaterol Hcl17$8,016
Tresiba Flextouch U-100Insulin Degludec15$7,077
Lantus SolostarInsulin Glargine,hum.Rec.Anlog50$4,236
Gabapentin125$3,323
Humalog Kwikpen U-100Insulin Lispro13$2,847
SymbicortBudesonide/Formoterol Fumarate13$2,783
Ezetimibe47$2,554
Atorvastatin Calcium318$2,161

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$127$49,28954 claims
PfizerEliquis$57$48,38856 claims
AstraZenecaFarxiga, Symbicort$101$27,19938 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,140 physician assistant providers in Iowa.

Other physician assistant in Muscatine

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →